Posted by Michael Wonder on 25 Apr 2026
‘Unviable’: 450,000 Australians to miss out on subsidised weight loss drug
24 April 2026 - An estimated 450,000 Australians will miss out on discounted weight loss medication after pharmaceutical giant Eli Lilly declined a recommendation to have the government subsidise its Mounjaro drug for people with type 2 diabetes.
The PBAC recommended on Friday that tirzepatide, a once weekly injectable medication sold as Mounjaro, be subsidised for adult patients with inadequately controlled type 2 diabetes.
